| Study Period | 2019 - 2030 |
| 乐鱼体育官网 Size (2025) | USD 0.54 Trillion |
| 乐鱼体育官网 Size (2030) | USD 1.12 Trillion |
| CAGR (2025 - 2030) | 15.76 % |
| Fastest Growing 乐鱼体育官网 | Asia Pacific |
| Largest 乐鱼体育官网 | North America |
| 乐鱼体育官网 Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Pharmaceutical Manufacturing 乐鱼体育官网 Analysis
The Pharmaceutical Manufacturing 乐鱼体育官网 size is estimated at USD 0.54 trillion in 2025, and is expected to reach USD 1.12 trillion by 2030, at a CAGR of 15.76% during the forecast period (2025-2030).
The pharmaceutical manufacturing 乐鱼体育官网鈥檚 growth can be attributed to factors such as increasing research and development expenditure by pharma contract manufacturing companies, advancements in pharmaceutical manufacturing technologies, the growing burden of chronic diseases, and the surge in the geriatric population. The increasing outsourcing volumes by pharmaceutical companies are further expected to propel 乐鱼体育官网 expansion over the coming years.
The growing burden of chronic diseases and the surging elderly population are expected to propel the demand for novel pharmaceuticals, thereby driving the pharmaceutical manufacturing 乐鱼体育官网. For instance, according to the American Cancer Society's 2023 update, around 1.93 million new cancer cases were diagnosed in 2023, compared to 1.9 million cases in 2022 in the United States. In addition, per the Centers for Disease Control's National Diabetes Statistics Report for 2022, the expenditure on diabetes in the United States was around USD 37.3 million in 2022. Thus, the high prevalence of chronic diseases globally is projected to spur the demand for pharmaceuticals, thereby driving the 乐鱼体育官网.
According to the pharmaceutical 乐鱼体育官网 analysis by the Australian Institute of Health and Welfare, the country recorded 14,800 lung cancer cases in 2023, compared to 14,529 lung cancer cases in 2022. Thus, such statistics are expected to propel pharma manufacturing, thereby facilitating 乐鱼体育官网 growth over the coming years.
The increasing emphasis of pharma contract manufacturing companies on expansion and the rising investments to bolster pharmaceutical production are anticipated to contribute to 乐鱼体育官网 growth. For instance, in December 2023, Piramal Pharma Solutions (PPS) invested GBP 45 million (USD 57.15 million) to establish a new manufacturing facility to produce antibody-drug conjugate (ADC) in Grangemouth, Scotland, United Kingdom. This helped the pharmaceutical manufacturing company bolster its ADC manufacturing capabilities.
In April 2022, Ferring Pharmaceuticals opened its integrated R&D and manufacturing facility in Hyderabad, with a total investment of EUR 30 million (USD 31.78 million). The manufacturing facility is designed to accelerate the manufacturing of solid dosage formulations. Owing to the above-mentioned factors, such as the rising burden of chronic disease and the expanding pharmaceutical sector, the pharma manufacturing 乐鱼体育官网 is expected to grow significantly over the forecast period.
The increasing research and development efforts by pharmaceutical and biopharmaceutical companies are further projected to accelerate pharmaceutical manufacturing, thereby supporting the 乐鱼体育官网鈥檚 growth. As per the European Federation of Pharmaceutical Industries and Associates data of June 2023, the R&D expenditure of European pharma companies increased from EUR 42,533 million in 2021 to EUR 44,500 million in 2022. Thus, the increasing R&D expenditure by pharmaceutical manufacturing companies is projected to spur pharma activities, including production, thereby supporting 乐鱼体育官网 expansion.
Advancements in pharmaceutical manufacturing technologies, the growing burden of chronic diseases, and the increasing R&D spending by pharma manufacturing companies are anticipated to support 乐鱼体育官网 growth over the coming years. However, the pricing pressure of biopharmaceutical and pharmaceutical companies and stringent regulations impede the 乐鱼体育官网's growth.
Pharmaceutical Manufacturing 乐鱼体育官网 Trends
The Biologics and Biosimilar Segment is Expected to Hold a Major Share in the Pharmaceutical Manufacturing 乐鱼体育官网
- The biologics and biosimilar segment is expected to hold a significant 乐鱼体育官网 share during the forecast period. A biological drug (biologics) is a product derived from living organisms or containing components of living organisms. Biologic drugs include various products from humans, animals, or microorganisms using biotechnology. Some of the major products, like vaccines, monoclonal antibodies, blood, and related products, fall into this category.
- The increasing demand and the rising product approvals of biologics are expected to propel the development and production of novel biologics further, thereby fueling the segment鈥檚 growth. For instance, the US Food and Drugs Administration approved 25 new biologics in 2023 compared to 14 in 2022. Thus, increasing biologics approvals are anticipated to bolster segment expansion over the coming years.
- The increasing emphasis on biosimilar manufacturing, owing to benefits like lower cost of development and similar efficacy like biologics, is anticipated to fuel segment expansion over the coming years. For instance, in May 2023, Sandoz invested EUR 25 million (USD 27 million) in its German manufacturing site to bolster its biosimilar manufacturing capabilities. Similarly, in June 2023, Pfizer Inc. and Samsung Biologics partnered for the long-term commercial manufacturing of Pfizer鈥檚 multi-product portfolio. This partnership propelled the manufacturing of biosimilars. Thus, the increased emphasis on biosimilar manufacturing is expected to boost segmental growth over the coming years.
- With the increasing significance of biologics and biosimilars, pharma contract manufacturing companies are undertaking several strategic movements, and such initiatives are projected to support segmental growth. For instance, in February 2023, Asahi Kasei Medical's US-based subsidiary Bionova Scientific, a full-service biologics CDMO, announced the expansion of its process development and GMP biologics manufacturing capacity. In addition, in July 2022, Biological E invested USD 217.31 million to expand its vaccine manufacturing capacity, along with generic injectables manufacturing. Thus, such initiatives are projected to foster segmental growth over the coming years.
- Thus, the increasing demand for biologics/biosimilars, increasing approvals of novel biologics, and rising emphasis on biosimilar manufacturing is projected to support the manufacturing of biologics and biosimilars, thereby supporting segmental growth.
Understand The Key Trends Shaping This 乐鱼体育官网
Download PDF
North America is Expected to Hold a Significant Share in the 乐鱼体育官网 During the Forecast Period
- North America is expected to hold a significant 乐鱼体育官网 share due to the presence of key pharmaceutical manufacturers and the growing spending on pharma manufacturing. Increasing research and development expenditure, the growing burden of chronic diseases, and the increasing adoption of advanced pharmaceutical manufacturing technologies are projected to support the regional 乐鱼体育官网.
- As per the August 2023 update by the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), 6 in 10 adults in the United States had a chronic disease, and 4 in 10 adults had two or more chronic diseases, like heart diseases, diabetes, and cancer, in 2022. As per a July 2023 update from Health Canada, cardiovascular diseases were the most common diseases in the country, and around 1 in 12 Canadians had a diagnosed heart disease. Thus, the high burden of chronic diseases in the region is projected to propel the demand for pharmaceuticals, thereby fostering their production.
- As per pharmaceutical 乐鱼体育官网 analysis, the rising adoption of advanced pharmaceutical manufacturing technologies in the United States and increasing efforts from various pharmaceutical manufacturers to adopt novel production technologies are expected to drive regional 乐鱼体育官网 growth. In January 2024, Enzene Biosciences, a CDMO, launched its first manufacturing site in the United States. The manufacturing site is integrated with a patented EnzeneX continuous manufacturing technology platform, and this is expected to serve innovative pharma and biopharmaceutical companies for their customized manufacturing requirements. In December 2022, the US Pharmacopeia opened an advanced manufacturing technology lab in Richmond. This laboratory helped pharma manufacturers with advanced manufacturing technologies, including continuous pharma manufacturing, to accelerate their production capabilities. Thus, the increasing uptake of novel production technologies is projected to augment regional 乐鱼体育官网 growth.
- The United States is one of the top pharma outsourcing destinations for pharma companies, owing to the presence of a significant number of CROs, CMOs, and CDMOs. Thus, such pharmaceutical contract manufacturing 乐鱼体育官网 trends are projected to bolster manufacturing activities in the country, thereby supporting regional 乐鱼体育官网 growth. For instance, according to Bioplan鈥檚 2022 Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, the United States was one of the top outsourcing destinations for pharmaceutical and biopharmaceutical research and manufacturing, owing to the presence of several contract manufacturers in the country.
- Thus, the pharmaceutical manufacturing 乐鱼体育官网 is expected to grow significantly over the forecast period due to the above-mentioned factors.
Get Analysis on Important Geographic 乐鱼体育官网s
Download PDF
Pharmaceutical Manufacturing Industry Overview
The pharmaceutical manufacturing 乐鱼体育官网 is highly competitive and fragmented, with the presence of several global and international players. The pharma contract manufacturing companies are adopting different growth strategies to enhance their 乐鱼体育官网 presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the top pharmaceutical manufacturing companies include Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Pfizer Inc., AstraZeneca, and Sanofi.
Pharmaceutical Manufacturing 乐鱼体育官网 Leaders
-
Pfizer Inc.
-
AstraZeneca
-
Sanofi
-
F. Hoffmann-La Roche Ltd
-
Eli Lilly and Company
- *Disclaimer: Major Players sorted in no particular order
Need More Details on 乐鱼体育官网 Players and Competiters?
Download PDF
Pharmaceutical Manufacturing 乐鱼体育官网 News
- January 2024: Samsung Biologics presented its 2024 business strategy at a conference held in the United States. At the conference, the company showed its commitment to accelerate its efforts to manufacture high-quality biomedicines to meet the evolving global demand.
- May 2023: MilliporeSigma, a business of Merck KGaA, expanded its contract, development, and manufacturing organization in the United States to bolster its manufacturing capabilities of antibody-drug conjugates and highly potent active pharmaceutical ingredients.
Pharmaceutical Manufacturing Industry Segmentation
As per the report's scope, pharmaceutical manufacturing is the industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry. Drug manufacturing can be broken down into unit operations, such as milling, granulation, coating, and tablet pressing.
The pharma manufacturing 乐鱼体育官网 is segmented by molecule type, drug development type, formulation, application, prescription type, and geography. By molecule type, the 乐鱼体育官网 is segmented into biologics and biosimilars (large molecules) and conventional drugs (small molecules). By drug development type, the 乐鱼体育官网 is segmented into outhouse and in-house. By formulation, the 乐鱼体育官网 is segmented into tablets, capsules, injectables, sprays, and other formulations. By application, the 乐鱼体育官网 is segmented into cancer, diabetes, cardiovascular diseases, neurological diseases, respiratory diseases, and other application types. By prescription type, the 乐鱼体育官网 is segmented into prescription medications and over-the-counter medications. The report also covers the 乐鱼体育官网 sizes and forecasts for major countries across different regions. For each segment, the 乐鱼体育官网 size is provided in terms of value (USD).
| By Molecule Type | Biologics and Biosimilars (Large Molecules) | ||
| Conventional Drugs (Small Molecules) | |||
| By Drug Development Type | Out-house | ||
| In-house | |||
| By Formulation | Tablets | ||
| Capsules | |||
| Injectables | |||
| Sprays | |||
| Other Formulations | |||
| By Application | Cancer | ||
| Diabetes | |||
| Cardiovascular Diseases | |||
| Neurological Diseases | |||
| Respiratory Diseases | |||
| Other Applications | |||
| By Prescription Type | Prescription Medications | ||
| Over-the-counter Medications | |||
| By Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Pharmaceutical Manufacturing 乐鱼体育官网 Research FAQs
How big is the Pharmaceutical Manufacturing 乐鱼体育官网?
The Pharmaceutical Manufacturing 乐鱼体育官网 size is expected to reach USD 0.54 trillion in 2025 and grow at a CAGR of 15.76% to reach USD 1.12 trillion by 2030.
What is the current Pharmaceutical Manufacturing 乐鱼体育官网 size?
In 2025, the Pharmaceutical Manufacturing 乐鱼体育官网 size is expected to reach USD 0.54 trillion.
Who are the key players in Pharmaceutical Manufacturing 乐鱼体育官网?
Pfizer Inc., AstraZeneca, Sanofi, F. Hoffmann-La Roche Ltd and Eli Lilly and Company are the major companies operating in the Pharmaceutical Manufacturing 乐鱼体育官网.
Which is the fastest growing region in Pharmaceutical Manufacturing 乐鱼体育官网?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Pharmaceutical Manufacturing 乐鱼体育官网?
In 2025, the North America accounts for the largest 乐鱼体育官网 share in Pharmaceutical Manufacturing 乐鱼体育官网.
What years does this Pharmaceutical Manufacturing 乐鱼体育官网 cover, and what was the 乐鱼体育官网 size in 2024?
In 2024, the Pharmaceutical Manufacturing 乐鱼体育官网 size was estimated at USD 0.45 trillion. The report covers the Pharmaceutical Manufacturing 乐鱼体育官网 historical 乐鱼体育官网 size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Pharmaceutical Manufacturing 乐鱼体育官网 size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Pharmaceutical Manufacturing Industry Report
The global pharmaceutical manufacturing 乐鱼体育官网 is segmented by molecule type, drug development type, formulation, application, prescription type, and geography. This comprehensive report offers a deep dive into the pharmaceutical manufacturing industry, providing a detailed analysis of key 乐鱼体育官网 drivers and 乐鱼体育官网 segments. The industry analysis highlights the growing prominence of biologics and biosimilars, with significant 乐鱼体育官网 growth observed in large molecules and conventional drugs.
The 乐鱼体育官网 report provides insights into the 乐鱼体育官网 size and 乐鱼体育官网 value, emphasizing the importance of in-house and out-house drug development. The industry research indicates a rise in demand for various formulations such as tablets, capsules, injectables, and sprays, driven by applications in cancer, diabetes, cardiovascular diseases, neurological diseases, and respiratory diseases.
The 乐鱼体育官网 segmentation also covers prescription medications and over-the-counter medications, with a detailed 乐鱼体育官网 overview of regional trends across North America, Europe, Asia-Pacific, The Middle East and Africa, and South America. The 乐鱼体育官网 forecast predicts continued growth, supported by industry trends and 乐鱼体育官网 data.
The industry outlook suggests that 乐鱼体育官网 leaders are focusing on innovative drug development and formulation techniques. The 乐鱼体育官网 review reveals that the pharmaceutical manufacturing 乐鱼体育官网 is driven by advancements in monoclonal antibodies, vaccines, and cell & gene therapy. The industry statistics and 乐鱼体育官网 predictions point towards a robust growth rate, with a significant impact on the 乐鱼体育官网 value.
The report example and report pdf provide further industry information, including insights into 乐鱼体育官网 leaders and research companies. The 乐鱼体育官网 outlook and 乐鱼体育官网 predictions are based on detailed industry reports and industry sales data. The industry size and 乐鱼体育官网 segmentation highlight the diverse applications and age groups, including children & adolescents, adults, and the geriatric population.
Overall, the 乐鱼体育官网 overview and 乐鱼体育官网 forecast indicate a positive industry outlook, with substantial growth opportunities driven by advancements in pharmaceutical manufacturing technologies and increasing demand for innovative drug formulations.
